iBio, Inc. Files 8-K with Material Agreements and Equity Sales

Ticker: IBIO · Form: 8-K · Filed: 2025-01-02T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, equity-sale, sec-filing

TL;DR

iBio dropped an 8-K detailing material agreements and equity sales. Check the filings.

AI Summary

On December 31, 2024, iBio, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. This 8-K filing includes financial statements and exhibits.

Why It Matters

This filing provides crucial updates on iBio's financial activities and material agreements, which could impact its stock price and investor confidence.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can indicate significant corporate actions and potential dilution.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by iBio, Inc. on December 31, 2024?

The filing indicates the entry into a Material Definitive Agreement on December 31, 2024, but the specific details of this agreement are not fully elaborated in the provided excerpt, requiring further review of the full document.

What type of equity securities were sold by iBio, Inc. under the unregistered sales provision?

The filing mentions 'Unregistered Sales of Equity Securities' as an item information, but the specific type and amount of equity securities sold are not detailed in this excerpt.

What is the significance of the Regulation FD Disclosure mentioned in the filing?

A Regulation FD Disclosure is included, which means iBio, Inc. is providing non-public information to the public in a manner that prevents selective disclosure.

What financial statements and exhibits are included with this 8-K filing?

The filing lists 'Financial Statements and Exhibits' as an item information, indicating that these documents are part of the submission, though their content is not detailed in the provided text.

When was iBio, Inc. incorporated, and in which state?

iBio, Inc. was incorporated in Delaware, as stated in the filing.

From the Filing

0001420720-25-000001.txt : 20250102 0001420720-25-000001.hdr.sgml : 20250102 20250102073639 ACCESSION NUMBER: 0001420720-25-000001 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241231 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250102 DATE AS OF CHANGE: 20250102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25500233 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20241230x8k.htm 8-K iBio, Inc._December 31, 2024 0001420720 false 0001420720 2024-12-30 2024-12-30 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 31, 2024 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 8800 HSC Parkway Bryan , Texas 77807 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value per share IBIO NYSE American ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ Item 1.01. Entry Into a Material Definitive Agreement. Exclusive License Agreement On December 31, 2024, iBio, Inc. (the “Company”), entered into an exclusive agreement (the “License Agreement”) with AstralBio, Inc. (“AstralBio”), pursuant to which AstralBio has licensed to the Company, on an worldwide exclusive basis and with the right to grant sublicenses, u

View on Read The Filing